Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...
Merck (NYSE:MRK) on Thursday indicated a mixed outcome in two pivotal Phase 3 trials for its experimental HIV therapy ...
However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...
Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of ...
US pharma giant Merck has announced top-line results from two pivotal Phase III trials of the investigational, once-daily, ...
Merck (MRK) announced topline results from two pivotal Phase 3 trials of the investigational, oral, two-drug, single-tablet regimen of ...
(RTTNews) - Merck & Co Inc. (MRK), Thursday reported topline results from two pivotal Phase 3 trials evaluating the company's drug candidate islatravir in combination with its approved HIV drug ...
Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug ...
The investigational therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor.
U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...
Merck (NYSE:MRK) on Thursday indicated a mixed outcome in two pivotal Phase 3 trials for its experimental HIV therapy islatravir, administered orally in combination with its FDA-approved HIV ...
Merck's DOR/ISL regimen demonstrated non-inferiority to bART and BIC/FTC/TAF in two pivotal Phase 3 trials for adults with HIV-1. Both trials achieved primary safety objectives, with detailed ...